UCB FIRST LOOK: Two-year data in axSpA and PsA
UCB reveals 2-year follow-up data with Bimzelx in axSpA and PsA, showing consistent and sustained responses across the board. In PsA, we observe similar meaningful improvements between biologic-naïve and TNFi-IR patients, and in axSpA Bimzelx shows very little radiographic progression. We see a strong role to play for Bimzelx in both indications, and anticipate FDA approvals to come later this year.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.